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DObjective:We reviewed our experience with the operative management of patients with isolated nonnative mi-
tral valve infective endocarditis to better understand the outcome.
Methods: We reviewed the records of 39 patients operated on for isolated nonnative mitral valve infective en-
docarditis from January 1974 to June 2009.Median age of the group was 68 years. There were 23 (59%) women.
Prostheses were mechanical in 18 (46%) patients, biological in 18 (46%), and annuloplasty rings in 3 (8%).
Staphylococcus was present in 22 (56%) patients. Operative indications included valve dysfunction in 26
(67%) patients and heart failure in 22 (56%).
Results: Perivalvular abscess was present in 12 (31%) patients. Replacement valves were mechanical in 23
(59%) patients and biological in 16 (41%). Twenty (51%) patients received additional operative procedures.
Treatment-related mortality occurred in 8 (21%) patients, with age being the only factor predictive of mortality
(hazard ratio, 5.37). Follow-up of the survivors was 5.7 years. Six (18%) patients underwent repeat mitral
valve replacement including 3 who had an annulus abscess at the initial operation and 2 who had the prosthesis
sutured to the left atrial wall. There was 1 (4%) case of recurrent endocarditis in the group of 28 patients
who survived more than 1 year after the incident operation. Survival at 5 years was 48% (95% confidence
interval, 35%-67%).
Conclusions: Surgery for isolated nonnative mitral valve infective endocarditis carries increased operative risk.
Aggressive debridement and reconstruction of the annulus are paramount to achieving a good outcome. Surviv-
ing patients obtain high rates of cure and freedom from recurrent infective endocarditis. (J Thorac Cardiovasc
Surg 2014;147:349-54)The purpose of this article is to study and report outcomes of
patients operated on for isolated nonnative mitral valve in-
fective endocarditis. Infection of the nonnative mitral valve
is a serious condition associated with significant morbidity
and mortality. Fortunately, it is an uncommon problem, with
a reported incidence of less than 0.5% per patient-year.1
Owing to its rarity, there are few studies that have specifi-
cally studied the condition. Most surgical series report out-
comes of either mitral valve (native and nonnative) or
nonnative valve (aortic, mitral, or combined) infective en-
docarditis, but not specifically the outcomes of isolated non-
native mitral valve infective endocarditis.2-4 Still, these
same studies identify worse outcomes in patients with
nonnative over native valve and mitral over aortic valve
infective endocarditis.2-4 This article focuses on the selecte Divisions of Cardiovascular Surgerya and Infectious Diseasesb and the De-
ent of Biostatistics/Cardiovascular Surgery,c Mayo Clinic, Rochester, Minn.
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PATIENTS AND METHODS
Mayo Clinic Institutional Review Board approved the collection and
analysis of data for this study. We reviewed the prospectively collected da-
tabases of the Divisions of Infectious Disease and Cardiovascular Surgery,
Mayo Clinic, Rochester, Minnesota, to identify all patients treated for iso-
lated nonnative mitral valve infective endocarditis. We defined nonnative
mitral valve infective endocarditis as infection based on standard bacterio-
logic blood and tissue cultures of a mitral valve prosthetic ring or valve. In
the case of negative cultures, we did not perform additional testing such as
genomic sequencing. We excluded patients who had previous other valve
repair or replacement.
Between January 1, 1974, and June 1, 2009, 94 patients received treat-
ment for isolated nonnative mitral valve infective endocarditis. Sixty-five
(63%) patients received isolated medical therapy, and 39 (37%) patients
received mitral valve replacement in addition to medical therapy. These
39 patients who received operation form the basis for this study.
We reviewed each operative patient’s medical record. We collected data
about patient characteristics, operative findings and techniques, operative
morbidity andmortality, and follow-up outcomes to include recurrence of en-
docarditis, need for subsequent mitral valve operation, and survival. We que-
ried the Social Security Death Index to complete collection of survival data.
For the purposes of this study, we used the following definitions: oper-
ative mortality occurred within 30 days of the incident operation or during
the same hospital stay; treatment-related mortality occurred greater than 30
days from the operation and after hospital discharge related to the incident
infective endocarditis episode. Last, cure of infective endocarditis was de-
fined as microbiologic cure evidenced by negative blood cultures offrdiovascular Surgery c Volume 147, Number 1 349
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amination/visit.
Descriptive statistics for categorical variables reported are frequency
and percentage; continuous variables reported are median (range). We
compared categorical variables with the Fisher’s exact test and continuous
variables with the 2-sample t test or Wilcoxon rank sum test, where appro-
priate. We used logistic regression models to identify univariate and mul-
tivariate predictors of perioperative mortality. We report survival of
patients and survival as determined by type of prosthesis inserted using
Kaplan-Meier survival curves. All statistical tests were 2-sided.RESULTS
We report baseline patient characteristics of the 39 patients
in Table 1. Previous infective endocarditis occurred in 15
(38%) patients and involved the native mitral valve in 5
(33%) patients and the nonnative mitral valve in 10 (67%).
Additional preoperative findings included a classification of
early infective endocarditis (12 months after valve opera-
tion) in 12 (31%) patients and late infective endocarditis
(>12 months after valve operation) in 27 (69%). Medical
therapy included culture-directed antibiotic treatment for 46
days (5-222 days) and postoperative for 28 days (1-181 days).
Staphylococci were the most common causative bacteria
(22 patients, 56%). Specific isolates included methicillin-
sensitive Staphylococcus aureus in 10 (26%) patients,
coagulase-negative staphylococci in 9 (23%), methicillin-
resistant S aureus in 2 (5%), and a mixed infection owing
to coagulase-negative Staphylococcus and Streptococcus
in 1 (3%). The remaining 17 (44%) nonstaphylococcal bac-
terial causes included Enterococcus in 5 (13%) patients,
viridans group streptococci in 5 (13%), and negative
cultures in 3 (8%, occurring in 1995, 2002, and 2005),
Propionibacterium acnes in 2 (5%), Haemophilis parain-
fluenza in 1 (3%), and the fungusHomographiella aspergil-
lata in 1 (3%).
Infection included the following specific isolates in the
group of 12 patients with early infective endocarditis.TABLE 1. Patient characteristics
Variable Data
Age (y) 68.0 (15.8-82.3)
Patients 65 y 26 (67%)
Female gender 23 (59%)
No. of previous sternotomies
One 27 (69%)
Two 9 (23%)
Three 3 (8%)
Prosthesis type
Mechanical 18 (46%)
Biological 18 (46%)
Ring annuloplasty 3 (8%)
Preoperative ejection fraction
50% 30 (77%)
<50% 8 (21%)
Unknown 1 (3%)
Creatinine 1.8 mg/dL 6 (15%)
350 The Journal of Thoracic and Cardiovascular SurgThe most common isolate was coagulase-negative staphy-
lococci in 6 (50%) patients. The remaining isolates in-
cluded S aureus in 2 (17%) patients and Enterococcus,
H parainfluenza, H aspergillata, and negative culture in
1 each.
The reported indication(s) for operation included valve
dysfunction in 26 (67%) patients, heart failure in 22
(56%), embolism in 7 (18%), sepsis in 6 (15%), and hemo-
lysis in 1 (3%); 21 (54%) had more than 1 indication. Op-
erative status was elective in 23 (59%) patients, urgent in 15
(38%), and emergency in 1 (3%). Themedian time from di-
agnosis of infective endocarditis to operation was 11 days
(range, 0-259 days).
Operation included a cardiopulmonary bypass time of
113 minutes (59-207 minutes) and aortic crossclamp time
of 67 minutes (0-145 minutes). Perfusion temperature was
32C or more in 18 patients (46%), 28C or more and
less than 32C in 6 (15%), and less than 28C in 15
(38%). Myocardial protection included isolated antegrade
cardioplegia in 28 (72%) patients and combined antegrade
and retrograde cardioplegia in 9 (23%). In 1 (3%) patient,
the surgeon used intermittent aortic crossclamp with cold fi-
brillatory arrest. In another patient, in whom it was the
fourth mitral valve operation, the surgeon could not safely
control the aorta such that he replaced the mitral valve dur-
ing a 55-minute period of deep hypothermic circulatory
arrest.
Technical aspects of the mitral valve operation included
exposure of the mitral valve via a posterior interatrial
groove incision in 25 (64%) patients, a transseptal incision
in 13 (33%), and a dome of the left atrium incision in 1
(3%). There was gross evidence of active infection with tis-
sue destruction or vegetation in 34 (87%) patients. There
was no abscess cavity reported in 27 (69%) patients, an ab-
scess cavity that involved less than 50% of the circumfer-
ence of the mitral valve annulus in 10 (26%), and an
abscess cavity that involved 50% or more of the circumfer-
ence of the annulus in 2 (5%). One (3%) patient had ab-
scess cavity involvement of the aortomitral intervalvular
fibrosa that involved less than 50% of the circumference
of the mitral valve annulus There were 14 (36%) patients
in whom the mitral valve demonstrated dehiscence from
the annulus.
Operation included the removal of all infected material
from the mitral valve annulus. In addition, 20 (51%) pa-
tients received treatment of the annulus with a 10% phenol
solution as part of our local institutional practice. There
was 1 (3%) patient with less than 50% abscess cavity in-
volvement of the circumference of the mitral valve annulus
who received pericardial patch reconstruction of the annu-
lus before replacement of the new prosthesis. In 2 (5%) pa-
tients, the prosthesis was sutured to the left atrial wall
because of destruction of the mitral valve annulus. The re-
maining 36 (92%) patients received standard sutureery c January 2014
TABLE 3. Univariate analysis of factors associated with operative
mortality
Parameter Hazard ratio CI P value
Age 65 y 5.37 2.09-13.77 <.001
Operative indication
Heart failure 1.72 0.81-3.64 .156
Valve dysfunction 1.45 0.67-3.11 .343
Sepsis 0.84 0.29-3.64 .155
Status urgent/emergency 1.44 0.74-2.14 .322
Creatinine>1.8 mg/dL 1.61 0.97-2.68 .064
Ejection fraction 50% 1.52 0.56-4.09 .411
Operative status urgent/emergency 1.44 0.7-2.98 .322
Mitral valve annulus abscess
50% of annulus 1.32 0.58-3.0 .512
Active endocarditis* 1.12 0.39-3.23 .835
CPB time (min) 1.01 1-1.02 .114
ACC time (min) 1.01 0.99-1.02 .244
Staphylococcal organism 0.97 0.46-2.07 .941
Valvular dehiscence 0.86 0.41-1.81 .686
Type of mitral valve replacement 0.74 0.36-1.53 .421
Days from diagnosis to operation
14 d 0.73 0.35-1.51 .399
7 d 0.71 0.34-1.48 .355
CI, Confidence interval; CPB, cardiopulmonary bypass; ACC, aortic crossclamp.
*Defined by surgeon based on operative findings.
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placement included a mechanical prosthesis in 23 (59%)
patients and a biological prosthesis in 16 (41%). Twenty
(51%) patients received a concomitant operative procedure
(Table 2).
Operative mortality occurred in 5 (13%) patients. The
patient who underwent replacement of the mitral valve dur-
ing a period of hypothermic circulatory arrest died of mul-
tiple acute cerebral infarctions within the watershed area of
the brain consistent with hypoperfusion phenomena. Addi-
tional causes of mortality included stroke, cardiac arrest
from bradycardia, myocardial infarction, and multisystem
organ failure in 1 each.
Patients who died had the following characteristics.
Infections include S aureus in 2 patients, methicillin-
resistant S aureus in 1, coagulase-negative staphylococci in
1, and negative culture in 1. In 2 patients therewas an annular
abscess (both had S aureus). Operative status was urgent/
emergency in 4 patients and elective in 1.
We report univariate predictors of operative mortality in
Table 3. Importantly, staphylococcal infection (P ¼ .941),
presence of an annulus abscess (P ¼ .512), and operative
status (P ¼ .322) did not predict operative mortality. Age
was the only significant factor and after adjusting for it
with multivariate analysis (hazard ratio, 5.37; confidence
interval, 2.09-13.77; P<.001), nothing else turned out to
be significant.
Additional mortality occurred in 6 (15%) patients within
1 year of operation. Importantly, 3 patients died of
endocarditis-related complications that included sepsis,
mediastinitis, and recurrent endocarditis requiring repeat
mitral valve replacement. One of the remaining 3 deaths
was the result of cardioembolic stroke, and the other 2
deaths were the result of unknown causes. One patient
was lost to follow-up 6 days after operation but was alive
at 10.5 years after operation as indicated by query of the
Social Security Death Index. Median follow-up of the sur-
vivors was 5.7 years (range, 0.6-24.0).
Subsequent mitral valve replacement occurred in 6
(18%) of the 34 patients who survived the operativeTABLE 2. Concomitant procedures performed at time of mitral valve
replacement
Variable Data
Any additional procedure 20 (51%)
Tricuspid valve repair 10 (26%)
Suture closure of left atrial appendage 2 (5%)
Aortic valve replacement (done for aortic stenosis) 2 (5%)
Coronary artery bypass graft surgery 2 (5%)
Tricuspid valve replacement 1 (3%)
Ventricular aneurysm repair 1 (3%)
Repair of left ventricle/left atrial appendage fistula 1 (3%)
Femoral pseudoaneurysm repair 1 (3%)
Femoral artery replacement 1 (3%)
The Journal of Thoracic and Caperiod and included 4 who had a mechanical prosthesis
and 2 a biological prosthesis. One patient received repeat
operation for acute bacterial endocarditis. In 3 patients the
indication for repeat operation included severe paravalvu-
lar regurgitation not associated with infection. Both pa-
tients who had the prosthesis sutured to the left atrial
wall had severe paravalvular leak develop and received
subsequent mitral valve replacement, 1 at 60 days (patient
had a S aureus abscess at initial operation) and the other at
7.2 years after the index endocarditis operation. Of the 2
patients who did not have paravalvular leak/valvular de-
hiscence, 1 received replacement of a dysfunctional
Ionescu-Shiley valve, and 1 received replacement because
of a stuck leaflet that occurred after resection of a subaortic
membrane.
Two patients had recurrent infective endocarditis and
underwent repeat mitral valve replacement. Both pa-
tients initially had late nonnative valve S aureus infec-
tive endocarditis and both had an annulus abscess at
their initial operation. One patient had a relapse of S au-
reus infective endocarditis 34 days after the initial oper-
ation. Subsequent mitral valve replacement proved very
difficult and the patient died of congestive heart failure
4 months after the repeat operation. A second patient
received successful medical treatment of recurrent iso-
lated nonnative mitral valve viridans group streptococci
infective endocarditis 4.3 years after the incident endo-
carditis operation. He subsequently had severe paravalv-
ular regurgitation develop and died during reoperationrdiovascular Surgery c Volume 147, Number 1 351
FIGURE 2. Kaplan-Meier estimated survival based on type of valve pros-
thesis inserted.
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endocarditis.
Overall outcomes included operative mortality in 5 pa-
tients, further treatment-related mortality in 3, repeat mitral
valve replacement in 6 (18%) patients, and recurrence of in-
fective endocarditis in 2 (6%). Of those patients who sur-
vived more than 1 year after operation, cure of the
endocarditis occurred in 27 of 28 (96%) patients. Treatment
of the annulus with phenol did not reduce the frequency of
the combined end point of repeat mitral valve replacement,
recurrent infective endocarditis, or infective endocarditis–
related death (P ¼ .52).
At last follow-up, 7 (18%) patients were alive, including
the patient lost to clinical follow-up (based on review of the
Social Security Death Index). Survival at 5 years was 48%
(95% confidence interval, 35%-67%). The figures show
the Kaplan-Meier estimated survival curves for operated
patients and age- and gender-matched controls (Figure 1).
In addition, we report survival based on type of valve pros-
thesis inserted (Figure 2).
COMMENTS
The present study describes our institution’s 35-year op-
erative experience in the treatment of patients with isolated
nonnative mitral valve endocarditis and the associated out-
comes of recurrent infective endocarditis, repeat mitral
valve operation, and survival. Most literature on the treat-
ment of patients with nonnative mitral valve infective endo-
carditis combines this group of patients with others such as
those with native mitral valve or nonnative aortic valve en-
docarditis.2,3 And in most of these series, the patients with
a nonnative mitral valve make up the minority of the cases
in the study. The present discussion focuses on the group of
patients with isolated nonnative mitral valve infective
endocarditis.
We found that the indications for operation in our series
were similar to those reported in other series and that sepsisFIGURE 1. Kaplan-Meier estimated survival for operated patients with
age- and gender-matched controls.
352 The Journal of Thoracic and Cardiovascular Surgwas an infrequent indication for operation. The majority of
our patients (54%) had more than 1 operative indication in-
cluding valve dysfunction (67%), heart failure (56%), em-
bolism (18%), or sepsis (15%). These operative indications
are similar to those in the report by Musci and colleagues,2
in which heart failure was an indication in 74% of patients,
with sepsis an indication in only 18%. The low rate of sep-
sis as an operative indication may represent a vague defini-
tion of sepsis or a selection bias on the part of the surgeon,
as Hill and colleagues5 showed that patients with sepsis are
at higher risk of death with operation. It is possible that pa-
tients with sepsis received initial medical management and
only after control of the sepsis were they taken to the oper-
ating room.
Most of the patients in our series received only standard
operative techniques of hypothermic cardiopulmonary by-
pass, cardioplegic arrest of the heart, and exposure of the
mitral valve through an incision posterior to the interatrial
groove or through the atrial septum. Through that exposure,
the surgeon removed all infected material, debrided the mi-
tral valve annulus, and in most of the patients (92%) used
only standard mitral valve replacement techniques to suture
in the prosthetic valve. Our aortic crossclamp time was 67
minutes, and that is not much different from that reported
by Exposito and colleagues6 (63 minutes) in their series
of 369 repeat mitral valve replacements for mostly non–en-
docarditis related indications.
We were probably not aggressive enough with mitral
annulus debridement and reconstruction. An annulus ab-
scess cavity was present in 12 (31%) of our patients,
and that is more frequent than the incidence reported by
Musci and colleagues,2 who reported an abscess in only
5% of patients. Importantly, we had 4 patients with an ab-
scess cavity, or with severe annulus destruction such that
the surgeon sutured the prosthesis to the left atrial wall,
in whom recurrent endocarditis or severe paravalvular re-
gurgitation developed, necessitating repeat mitral valve
operation. On the basis of this experience, we endorseery c January 2014
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cardial patch reconstruction of the mitral valve annulus as
needed before valve replacement as outlined by David and
colleagues.7-9
Recurrent valve infection remains a problem for patients
treated for nonnative mitral valve infective endocarditis. In
our series, infective endocarditis recurred in 2 (5%) pa-
tients and both had a S aureus infection and an annulus ab-
scess at the initial operation. It is possible that more
aggressive debridement, such as described above, could
have prevented recurrent infection. One patient died after
repeat mitral valve operation and 1 survived after medical
treatment. Sheikh and colleagues10 reported a similar fre-
quency of recurrence of infective endocarditis in their se-
ries from the Toronto General Hospital (9/87 mitral valve
replacement patients, 10%). Importantly, in that series, 2
patients underwent reoperation and both survived, whereas
7 patients received medical management and only 1 (14%)
survived. There appears to be a low, but important, risk of
recurrent infection in this patient group; should infection
recur, treatment should be individualized, inasmuch as sur-
vival has been reported with both medical and surgical
techniques.
There is risk of need for repeat mitral valve replacement
in patients treated with operation for isolated nonnative mi-
tral valve infective endocarditis. In our series, 6 (18%) of
the 34 patients who survived the initial operation underwent
repeat mitral valve replacement. We expect that we could
have reduced the need for repeat mitral valve replacement
had we been more aggressivewith debridement and annulus
reconstruction, as previously noted. Regardless, our experi-
ence is similar to that of Exposito and colleagues,6 who re-
ported the need for third timemitral valve replacement in 80
(22%) of 369 patients. Importantly, in that study, only 5%
of the patients who needed the second mitral valve replace-
ment had endocarditis; the remaining 95% of patients did
not have endocarditis and presumably represented a less
risky group of patients for valve replacement. However, Ex-
posito’s group reported a statistically significant relation-
ship between the need for reoperation and annular disease
that included endocarditis.
Urgent or emergency status is common in patients oper-
ated on for nonnative mitral valve infective endocarditis. In
our series, 41% of patients underwent operation in a non-
elective status, and that is similar to the 49% reported in
the study by Sheikh and associates10 from the Toronto Gen-
eral Hospital group. Despite the frequent urgent nature of
the operation, we report operative mortality in only 5
(12.5%) of our patients; that is similar to the 8.7% reported
by Sheikh and associates,10 but less than the 22.9% re-
ported by Wang, Athan, and Pappas11 in the International
Collaborative Study and the 32.8% reported by Musci
and colleagues.2 In our study, operative status did not pre-
dict operative morality (P ¼ .322).The Journal of Thoracic and CaOperative mortality may not be an appropriate time
frame to evaluate the mortality rate and clinical outcome
of surgery in infective endocarditis, as pointed out byMusci
and coworkers.3 In that regard, we noted 3 additional
endocarditis-related deaths within 1 year of operation, and
an endocarditis-related death occurred in 21% of our pa-
tients (8/39). Musci and associates2 also reported a higher
1-year mortality (49%), but they did not report the
endocarditis-related mortality. Multivariate analysis in our
study identified age as the only factor significantly associ-
ated with survival, whereas Musci and coworkers2 reported
nonelective operative status, preoperative renal insuffi-
ciency (not otherwise defined), and cardiogenic shock (intu-
bated on arrival to the hospital) placed patients at higher risk
of death.
Survival after operation is not affected by valve prosthesis
type. In our series, the 1- and 5-year survival rates after bi-
ological valve implantation were 69%  23% and
38%  25%; after mechanical valve implantation they
were 74%  18% and 56%  21%, the differences of
which were not significant. In a like manner, Musci and as-
sociates2 reported that comparison of survival rates after the
implantation of biological or mechanical prostheses showed
no differences in the groups out to 10 years. Moon and col-
leagues,12 from the Stanford University group, reported
similar survival rate findings; however, long-term freedom
from reoperation for patients less than 60 years who re-
ceived a biological prosthesis was low, around 50% at 10
years. On the basis of these data, we recommendmechanical
valve replacement tomost patients under the age of 60 years.
There are 3 main limitations to this study: small number
of patients, extensive time period of study, and retrospective
design. These limitations are related to the rare occurrence
of this condition, which makes it unlikely that any single in-
stitution could gather a large enough number of cases over
a reasonable period of time in which to report pertinent
outcomes. It would only be through a prospective multi-
institution registry, such as is availablewith aortic dissection
and pericarditis, that a large enough experience could be
garnered. Of these limitations, the extensive time period
of study probably affects the results the most. We would
expect, however, that just as operative mortality for other
cardiac conditions has decreased over time, such would be
the case for operation in the setting of nonnativemitral valve
infective endocarditis, too; although, we cannot measure or
analyze such an occurrence given the rarity of the condition.
Nonnative mitral valve infective endocarditis is a rare but
serious condition associated with reduced survival. It re-
mains a surgical challenge complicated by frequent
presence of paravalvular abscess, need for annulus recon-
struction, and need for concomitant operative procedure,
all of which make an already difficult situation more com-
plex. Aggressivemitral valve annulus debridement and peri-
cardial patch reconstruction are paramount to a successfulrdiovascular Surgery c Volume 147, Number 1 353
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mortality remain high and intermediate-term survival rates
are less than in age- and gender-matched controls. However,
freedom from recurrent infection in patients who survive the
incident infective event is over 95%, and we believe that is
the basis for an aggressive surgical approach.References
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